Improve early diagnosis of Parkinsons
- Trial ID
- NCT07509125
- Official Title
- Ultra-High Resolution PET of the Human Brain and Spinal Cord in Healthy Aging, Dementia, Movement Disorders, ALS and Psychotic Disorders
- Goal
- Improve early diagnosis of Parkinsons
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
- Study Type
- INTERVENTIONAL
- Enrollment
- 300 participants
- Conditions
- Alzheimer Dementia (AD), ALS - Amyotrophic Lateral Sclerosis, Parkinson s Disease, REM Sleep Behavior Disorder (iRBD), PSP - Progressive Supranuclear Palsy, MSA - Multiple System Atrophy, Dementia With Lewy Bodies (DLB), ALS With Frontotemporal Dementia (ALS/FTD), Adult Onset Psychotic Disorder, Very Late Onset Psychotic Disorder
- Interventions
- UHR PET/CT scan of the brain with ¹⁸F-FDG, UHR PET/CT scan of the brain with ¹⁸F-PE2I, UHR PET/CT scan of the brain with ¹⁸F-SynVesT-1, UHR PET/CT scan of the brain with ¹⁸F-MK6240, 3T MRI imaging of the brain
Plain-Language Summary
The goal is to create ultra-high resolution maps of metabolism, dopamine terminals, synapses and tau in the brain and spinal cord, so clinicians can better tell Parkinson's and related disorders apart and spot early changes. Participants get PET scans with 18F-FDG to measure glucose use, 18F-PE2I to image dopamine transporters and reveal nigrostriatal nerve terminal loss, 18F-SynVesT-1 to quantify synaptic density, and 18F-MK6240 to detect tau, plus a 3T MRI; these are diagnostic imaging tests, they do not treat symptoms and do not interact with levodopa. The study enrolls healthy adults and people with a range of conditions, including Parkinson's, dementia syndromes, ALS, movement disorders, REM sleep behavior disorder and psychosis. For Parkinson's specifically, adults aged 18 to 90 with clinically established PD by MDS criteria, an abnormal 18F-PE2I PET, and no significant cognitive impairment (MoCA 26 or higher) who can tolerate PET/MRI are eligible.
Locations
- UZ Leuven, Leuven, Vlaams-Brabant, Belgium
Frequently Asked Questions
- What is this trial testing?
- This trial is studying UHR PET/CT scan of the brain with ¹⁸F-FDG. The goal is to create ultra-high resolution maps of metabolism, dopamine terminals, synapses and tau in the brain and spinal cord, so clinicians can better tell Parkinson's and related disorders apart and spot early changes. Participants get PET scans with 18F-FDG to measure glucose use, 18F-PE2I to image dopamine transporters and reveal nigrostriatal nerve terminal loss, 18F-SynVesT-1 to quantify synaptic density, and 18F-MK6240 to detect tau, plus a 3T MRI; these are diagnostic imaging tests, they do not treat symptoms and do not interact with levodopa. The study enrolls healthy adults and people with a range of conditions, including Parkinson's, dementia syndromes, ALS, movement disorders, REM sleep behavior disorder and psychosis. For Parkinson's specifically, adults aged 18 to 90 with clinically established PD by MDS criteria, an abnormal 18F-PE2I PET, and no significant cognitive impairment (MoCA 26 or higher) who can tolerate PET/MRI are eligible.
- Who can participate?
- Participants must be between 18 Years and 90 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 3 years and 7 months.